Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and BioSciences Division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD). In August 2013, Emergent Biosolutions Inc closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. In February 2014, the Company acquired Cangene Corporation.